Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted radiation may extend life for patients with limited bone metastases

NCT ID NCT03143322

Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with good overall health are taking part. The goal is to see if the extra radiation improves how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

168 people

The number who actually took part.

Started

Jul 2018

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients older than 18 years and younger than 75 years 2. Good general condition: WHO performance status ≤ 2 3. Patients with histological proof of breast, non-small cell lung, or prostate cancer Note: Histological proof can be done on the primitive tumour and/or adenopathy and/or metastatic site. 4. Absence of co-morbidity contra-indicating radio-chemotherapy or surgery 5. Primary tumor accessible to curative-intent treatment (surgery, chemoradiation…) for patients with synchronous metastases 6. Patients with between 1 and 5 synchronous or metachronous bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if necessary) within 6 weeks before randomization) 7. Bones metastases treatable by SBRT 8. Primary cancer considered to be controlled or accessible to curative-intent treatment (surgery, chemoradiation…) in case of locoregional recurrence for metachronous bone oligo-metastatic disease 9. Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy 10. Patients who have received the information sheet, dated and signed the informed consent form 11. Affiliated to the social security system Exclusion Criteria: 1. Visceral metastases as defined by FDG-PET (F-Choline-PET or PSMA PET-CT for prostate cancer) and cerebral CT or MRI performed. 2. Previous systemic therapy for metastasis for patients with metachronous metastasis. Prostate and breast cancer patients remain eligible if hormonal treatment was initiated 6 months before enrollment 3. All bone metastasis requiring surgical treatment (spinal cord compression, fracture…) 4. More than 5 bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if spinal bone metastases on NaF-PET) 5. Previous cancer within the 5 years before inclusion (except basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix) 6. Previous radiotherapy on bone metastasis (e.g: antalgic radiotherapy) 7. Patient enrolled in another therapeutic trial 8. Pregnant women or breast feeding mothers, 9. Hypersensitivity to the active substance (FDG and NaF or F-Choline or PSMA for prostate cancer) or to any of the excipients 10. Contraindication to MRI (in case of spinal metastases) 11. Patients deprived of liberty or placed under the authority of a tutor. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. Patients unable to understand the purpose of the study (language, etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm lung neoplasm metastatic carcinoma in the bone metastatic malignant neoplasm metastatic prostate carcinoma non-small cell lung carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone metastases Metastatic breast cancer Metastatic lung cancer Metastatic prostate cancer

Contacts and locations

Locations

  • Centre Amethyst CROM

    Creil, France

  • Centre Catalan D'Oncologie

    Perpignan, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre Léon Bérard

    Lyon, France

  • Centre Léonard de Vinci

    Dechy, France

  • Centre Marie Curie

    Arras, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Pierre Curie

    Beuvry, France

  • Centre d'oncologie et radiothérapie Saint-Jean

    Saint-Doulchard, France

  • Centre de Cancérologie du Grand Montpellier

    Montpellier, France

  • Chu Grenoble

    Grenoble, France

  • Clinique Ambroise Pare

    Beuvry, France

  • Clinique Tivoli Ducos

    Bordeaux, France

  • Clinique des dentellières

    Valenciennes, France

  • GCS RISSA - Institut de cancérologie Paris Nord

    Sarcelles, France

  • Hôpital Henri Mondor

    Créteil, France

  • Hôpital Métropole Savoie

    Chambéry, France

  • Hôpital Privé Le Bois

    Lille, France

  • Hôpital Privé Les Bonnettes

    Arras, France

  • ICO - Site Paul Papin

    Angers, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Jean Godinot

    Reims, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut Sainte Catherine

    Avignon, France

  • Institut de Cancérologie de Bourgogne

    Dijon, France

  • Institut de Cancérologie de Lorraine

    Nancy, France

  • Institut de Cancérologie de l'Ouest

    Nantes, France

  • Pôle Leonard de Vinci

    Chambray-lès-Tours, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.